Peptide research profile

Oxytocin

Also known as Oxytocin+ · OXT

An endogenous cyclic nonapeptide hormone with established obstetric uses and a broad intranasal behavioral-research literature. Effects are route-, dose-, context-, and population-dependent.

  • Endocrine & reproductive
Established human evidence3 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The calculator contains 100–200 mcg mass-based rows. Intranasal behavioral trials generally report IU, while regulated obstetric use follows entirely different monitored protocols. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset100–200 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo universal research ceiling
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Do not convert IU to mcg or syringe units without the exact product potency. Oxytocin preparations are commonly labeled by international units.

Schedule literacy

Patterns described in source material

  • Daily in recorded presets

    The cadence represented by the recorded calculator presets.

  • 8–48 IU intranasal in many behavioral trials

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context
  • 8 or 24 IU · Single intranasal sessionsDose-response social-cognition trialDevice-specific
  • 48 IU total/day · Intranasal for 24 weeksSOARS-B autism trialPrimary endpoint negative

Human research is extensive but indication- and route-specific; no single intranasal schedule is established across outcomes.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Obstetric physiology

    Regulated injectable products are used for specific labor and postpartum indications under monitoring.

  • 02

    Social-cognitive research

    Intranasal studies examine social salience, trust, anxiety, and neural responses.

  • 03

    Dose and delivery

    Breath-powered and standard nasal devices produce different deposition and dose-response findings.

  • 04

    Context dependence

    Sex, baseline traits, task, timing, and social context can change observed effects.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Large but heterogeneous intranasal literature

    Many small studies use 24 IU, while systematic reviews find inconsistent clinical outcomes.

  • Human

    Negative autism phase 2 trial

    A 24-week pediatric trial using a target 48 IU/day did not improve the primary social-withdrawal outcome.

  • Review

    No universal intranasal dose

    Modern reviews emphasize non-linear dose response and delivery-device effects.

Recorded protocol library

Amounts recorded for Oxytocin

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Lower recorded

    100 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Cyclic neurohypophyseal peptide hormone
Sequence
CYIQNCPLG-NH2
Amino acids
9
Approx. MW
1007.2 Da
Origin / design
Endogenous hypothalamic hormone released from the posterior pituitary

Important limitations

  • IU, micrograms, route, formulation, and delivery device are not interchangeable.
  • Obstetric oxytocin can cause serious harm without clinical monitoring.
  • Acute social-task effects do not establish treatment of psychiatric conditions.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

3 curated references

  1. Advances in the field of intranasal oxytocin research: lessons learned and future directionsMolecular Psychiatry · 2021 · Review
  2. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum DisorderNew England Journal of Medicine · 2021 · Human
  3. Dose-dependent social-cognitive effects of intranasal oxytocin in adults with autismTranslational Psychiatry · 2017 · Human

Related profiles